Benjamin Zohar, NCACIP

Wellbutrin (Bupropion) Withdrawal: Symptoms & Timeline

Benjamin Zohar, NCACIP -
Medical illustration about Wellbutrin (bupropion) withdrawal symptoms, expected timeline, and discontinuation after stopping the medication.

Quick Answer: Bupropion (Wellbutrin) can cause discontinuation symptoms — irritability, insomnia, headache, nausea, and low mood — particularly when stopped abruptly. The syndrome is generally milder and less common than with SSRIs or SNRIs because bupropion is non-serotonergic and has a comparatively long elimination half-life. Any decision to stop should be planned with the prescribing clinician.

Key Takeaways

  • Bupropion is an NDRI (norepinephrine–dopamine reuptake inhibitor), not an SSRI or SNRI — its discontinuation profile is different from serotonergic antidepressants.
  • Discontinuation symptoms, when they occur, typically emerge within days, peak in the first one to two weeks, and resolve within two to four weeks.
  • Classic serotonergic discontinuation features such as "brain zaps" and sensory disturbances are uncommon with bupropion alone.
  • Antidepressant discontinuation symptoms are a physiological readjustment, not addiction — bupropion does not produce compulsive use at prescribed doses.
  • Bupropion carries a dose-related seizure warning, which is one reason all dose changes should be clinician-managed rather than self-directed.
  • Symptoms persisting beyond roughly four weeks more likely represent recurrence of the underlying depression or anxiety than discontinuation, and warrant prompt clinical follow-up.

Table of Contents

Does Wellbutrin Cause Withdrawal?

Yes — bupropion can cause discontinuation symptoms, but they are less frequent and generally milder than the discontinuation syndrome associated with SSRIs and SNRIs. Two pharmacologic features explain most of the difference: bupropion does not act primarily on serotonin, and its elimination half-life (roughly 21 hours for the parent compound, with active metabolites persisting longer) means blood levels decline gradually rather than dropping off a cliff when a dose is missed.

In practical terms, many patients who reduce bupropion under medical supervision report little or no difficulty. Symptoms are more likely after abrupt cessation, higher doses, or long treatment duration. For a consumer-facing walkthrough of what patients typically experience, Palm City Wellness has published a plain-language companion guide, Wellbutrin Withdrawal: Symptoms, Timeline, and What to Expect, written for people currently taking the medication and their families.

Discontinuation Is Not Addiction: Why the Language Matters

Antidepressant discontinuation symptoms reflect neuroadaptation — the body readjusting after a medication is removed — not a substance use disorder. Bupropion taken as prescribed does not produce cravings, compulsive use, or the loss-of-control pattern that defines addiction. Conflating the two discourages appropriate antidepressant treatment and stigmatizes patients who need it.

This distinction between physiological dependence and addiction is one of the most persistent sources of confusion in public drug education, and it is why precise, person-first, non-stigmatizing language matters in clinical writing. It is the same distinction that applies when patients ask whether needing a medication means they are "addicted" to it. For a definitional treatment of related recovery terminology, see our glossary entries on abstinence and relapse.

Bupropion Discontinuation Symptoms

When discontinuation symptoms occur after stopping bupropion, the most commonly reported include:

  • Irritability or agitation
  • Anxiety or restlessness
  • Insomnia or vivid dreams
  • Headache
  • Nausea or gastrointestinal upset
  • Fatigue and low energy
  • Difficulty concentrating ("brain fog")
  • Dizziness
  • Return of depressive symptoms or low mood

Notably absent from that list are the electric-shock sensations ("brain zaps"), paresthesia, and vertigo that characterize serotonergic discontinuation. When a patient stopping bupropion reports those symptoms, clinicians should ask what else was stopped at the same time.

Clinical Pearl: Bupropion is frequently prescribed as augmentation alongside an SSRI or SNRI. When a patient reports "brain zaps from stopping Wellbutrin," screen for concurrent serotonergic discontinuation — patients often stop both medications simultaneously, and the sensory symptoms almost always belong to the serotonergic agent, not the bupropion.

Wellbutrin Withdrawal Timeline

There is no universal timeline — dose, duration of treatment, formulation (immediate-release, SR, XL), and whether the medication was tapered or stopped abruptly all shape the course. The general pattern reported in the discontinuation literature looks like this:

Phase Typical timing What is commonly reported
Onset Days 1–4 after last dose Delayed onset relative to shorter-acting antidepressants because of bupropion's longer half-life; irritability, headache, and sleep disturbance appear first
Peak Week 1–2 Symptoms reach maximum intensity, then begin easing as the body adjusts
Resolution Weeks 2–4 Most discontinuation symptoms resolve
Beyond 4 weeks Ongoing symptoms Persistent low mood, anxiety, or cognitive complaints more likely represent recurrence of the underlying condition — clinical reassessment indicated

Bupropion vs. SSRI/SNRI Discontinuation

The comparison below summarizes why bupropion discontinuation is generally regarded as the milder syndrome. The FINISH mnemonic (Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, Hyperarousal) was developed to describe serotonergic antidepressant discontinuation and maps poorly onto bupropion.

Feature Bupropion (Wellbutrin) SSRIs / SNRIs
Drug class NDRI (norepinephrine–dopamine reuptake inhibitor) Serotonergic reuptake inhibitors
Discontinuation frequency Less common Common, especially with short-half-life agents (e.g., paroxetine, venlafaxine)
"Brain zaps" / sensory disturbances Uncommon Characteristic
Typical severity Mild to moderate Mild to severe; can be disabling with abrupt cessation of short-acting agents
Onset after last dose Often delayed (longer half-life) Frequently within 1–3 days
Distinct safety concern Dose-related seizure risk with dosing errors or abrupt changes in regimen Serotonin-related discontinuation syndrome (FINISH)

The Seizure Consideration

Bupropion's FDA labeling carries a dose-related seizure warning, and seizure risk is concentrated in scenarios involving high doses, rapid dose escalation, or use in patients with predisposing conditions. This is a core reason self-directed changes to a bupropion regimen — stopping, restarting, doubling a missed dose — are discouraged in the labeling and in clinical practice.

It is worth distinguishing this from withdrawal-seizure risk seen with CNS depressants: abrupt discontinuation of benzodiazepines such as Xanax, Valium, Ativan, and Klonopin can itself provoke seizures as a withdrawal phenomenon, which is a fundamentally different mechanism and a medically more dangerous discontinuation scenario. Bupropion discontinuation is not associated with withdrawal seizures — the seizure concern with bupropion attaches to taking the drug, not stopping it.

Discontinuation Symptoms vs. Recurrence of Depression

The single most important clinical judgment after stopping any antidepressant is separating short-lived discontinuation symptoms from the return of the condition the medication was treating. Three features favor recurrence over discontinuation:

  • Timing: discontinuation symptoms cluster in the first two weeks; recurrent depression typically emerges later and builds gradually.
  • Character: discontinuation symptoms tend to be physical and mixed (headache, nausea, sleep disruption); recurrence looks like the patient's original episode.
  • Trajectory: discontinuation symptoms fade steadily; recurrence persists or worsens beyond roughly four weeks.

The terminology parallel with substance use disorders is imperfect but instructive: in addiction medicine, a return of symptoms after remission is discussed in the contested vocabulary of relapse and recurrence, and the same care with language applies here — a patient whose depression returns after stopping an antidepressant has a recurring illness, not a "failed" discontinuation.

Genuine withdrawal syndromes — the kind requiring medically managed discontinuation — are covered elsewhere in our clinical library, including 7-OH withdrawal symptoms and timeline and buprenorphine-based management of kratom and 7-OH withdrawal. Bupropion discontinuation does not belong in that category.

Tapering: General Principles (Not a Schedule)

When clinicians choose to taper bupropion, the approach is individualized to dose, formulation, treatment duration, and prior discontinuation experience. Some patients discontinue over weeks; others need longer. Recent literature on antidepressant tapering more broadly (e.g., Horowitz & Taylor, 2019) argues for slower, proportionate dose reductions than older guidance suggested, though most of that work concerns serotonergic agents.

Deliberately, this article does not provide a taper schedule. Discontinuation planning is a prescriber-level decision, and published self-directed schedules are exactly the kind of guidance that goes wrong when applied to the wrong patient. Involuntary abrupt discontinuation is also a real-world problem worth naming: patients forced off a medication by supply disruption — as seen during the ongoing Adderall shortage — face discontinuation effects without any of the planning described here, and should contact their prescriber rather than waiting it out.

Myth vs. Fact

Myth Fact
"If stopping Wellbutrin causes symptoms, that means it's addictive." Discontinuation symptoms are physiological readjustment. Bupropion does not produce cravings or compulsive use at prescribed doses and is not considered addictive.
"Bupropion's long half-life means it's safe to stop cold turkey." The long half-life softens the drop-off but does not eliminate discontinuation symptoms or the risk of rapid symptom recurrence. Cessation should still be clinician-guided.
"Brain zaps are a typical Wellbutrin withdrawal symptom." Sensory disturbances are characteristic of serotonergic discontinuation, not bupropion. Their presence suggests a co-stopped SSRI/SNRI.
"Symptoms six weeks after stopping are still withdrawal." Symptoms persisting beyond about four weeks more likely represent recurrence of the underlying depression or anxiety and need clinical reassessment.

When to Seek Help

Anyone considering stopping bupropion should start with the prescribing clinician. Prompt medical contact is warranted if discontinuation symptoms interfere with daily functioning, if low mood or anxiety returns or worsens after stopping, or if symptoms persist beyond a few weeks. Any emergence of thoughts of self-harm requires immediate attention — in the United States, the 988 Suicide & Crisis Lifeline is available by call or text, 24/7.

Because antidepressant decisions are inseparable from the underlying condition being treated, patients struggling with recurrent depression or anxiety after a medication change may benefit from structured mental health treatment rather than medication adjustment alone. Clinicians and families supporting someone through this can find additional educational resources throughout the Integrated Recovery & Intervention Education Network (IRIEN) library.

Frequently Asked Questions

How long does Wellbutrin withdrawal last?

When discontinuation symptoms occur, they typically begin within the first few days, peak during weeks one to two, and resolve within two to four weeks. Symptoms lasting beyond about a month more likely reflect recurrence of the underlying depression or anxiety and should be evaluated by a clinician.

Is Wellbutrin withdrawal dangerous?

Bupropion discontinuation is generally mild and is not associated with withdrawal seizures or medically dangerous withdrawal, unlike benzodiazepine or alcohol withdrawal. The primary risk of stopping is rapid recurrence of depression or anxiety, which is why discontinuation should be planned with the prescriber.

Can you stop Wellbutrin cold turkey?

Abrupt cessation is generally discouraged. Bupropion's long half-life makes cold-turkey discontinuation less jarring than with short-acting antidepressants, but it still raises the likelihood of discontinuation symptoms and rapid return of the underlying condition. The prescribing clinician should set the plan.

Is Wellbutrin addictive?

No. Bupropion taken as prescribed does not cause cravings or compulsive use and is not considered addictive. Discontinuation symptoms reflect the body readjusting after the medication is removed, which is physiological dependence — a different phenomenon from addiction.

Does Wellbutrin cause brain zaps?

Rarely on its own. Electric-shock sensations and other sensory disturbances are characteristic of stopping serotonergic antidepressants (SSRIs and SNRIs). A patient reporting brain zaps after stopping bupropion has often stopped a serotonergic medication at the same time.

Is Wellbutrin an SSRI?

No. Bupropion is an NDRI — a norepinephrine–dopamine reuptake inhibitor. Its non-serotonergic mechanism is one reason its discontinuation profile is milder than that of SSRIs and SNRIs.

What is the difference between discontinuation symptoms and relapse of depression?

Discontinuation symptoms appear early (first two weeks), are often physical, and fade steadily. Recurrence of depression emerges later, resembles the person's original episode, and persists or worsens. Symptoms continuing past roughly four weeks favor recurrence and warrant clinical reassessment.

Why does bupropion have a seizure warning?

Bupropion carries a dose-related seizure risk while taking the medication — associated with high doses, rapid escalation, or predisposing conditions — not a withdrawal-seizure risk from stopping it. This is a key reason dose changes should always be managed by the prescriber.

References

  1. U.S. Food and Drug Administration. Wellbutrin (bupropion hydrochloride) prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
  2. National Library of Medicine, MedlinePlus. Bupropion. https://medlineplus.gov/druginfo/meds/a695033.html
  3. Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. American Family Physician. 2006;74(3):449–456. https://www.aafp.org/pubs/afp/issues/2006/0801/p449.html
  4. Gabriel M, Sharma V. Antidepressant discontinuation syndrome. CMAJ. 2017;189(21):E747. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449237/
  5. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538–546. https://pubmed.ncbi.nlm.nih.gov/30850328/
  6. National Institute of Mental Health. Depression. https://www.nimh.nih.gov/health/topics/depression
  7. 988 Suicide & Crisis Lifeline. https://988lifeline.org/

Last updated: July 6, 2026

Written by Benjamin Zohar, NCACIP — Nationally Certified Advanced Clinical Intervention Professional; ISSUP New York Network Moderator.
Edited and medically reviewed by Brandon McNally, RN — ICU Critical Care Nurse.